Acalabrutinib shine mai hana tyrosine kinase (BTK) na ƙarni na biyu, sabon magani wanda zai iya inganta rayuwar cutar sankarar bargo ta lymphocytic (CLL) da lymphoma na mantle cell (MCL).
Masu binciken sun yi imanin cewa masu hana BTK da aka haɗa tare da magungunan CD20 da aka gyara (irin su Obinutuzumab) na iya inganta sauri da zurfin jiyya na Acalabrutinib ta hanyar mayar da martani ga ƙwayoyin ciwon daji masu tasowa.
A cikin gwaji na asibiti na Phase 1 b / II, masu binciken sun kimanta tasirin haɗin gwiwar Acalabrutinib da Obinutuzumab a Cibiyar Ciwon Kankara ta Jami'ar Jihar Ohio-James Cancer Hospital-Richard Research Center (OSUCCC-James), tare da haɗuwa da 45 da suka sake komawa / refractory. ko marasa lafiya na CLL waɗanda ba su taɓa samun magani ba.
Gabaɗaya, haɗin haɗin gwiwa na Acalabrutinib da Obinutuzumab yana da kyau a yi haƙuri, kuma adadin amsa ya inganta akan lokaci.
Daga cikin marasa lafiyar da ba su sami wani magani ba, yawan amsawar gabaɗaya shine 95%. Tsakanin lokacin bin diddigin ya kasance watanni 17.8. Matsakaicin adadin tsira gabaɗaya (OS) na marasa lafiya tare da CLL da suka koma baya / mai hanawa ya kasance 92%, tare da tsaka-tsakin lokaci na watanni 21.
OSUCCC-James. Mataimakiyar farfesa kuma marubuciyar farko Jennifer Woyach ta ce duk da ci gaban da aka samu wajen maganin CLL a shekarun baya-bayan nan, har yanzu bukatar karin hanyoyin magani na cikin gaggawa.
The overall effectiveness of the Acalabrutinib trial emphasizes that this clinical study may have a potential impact on the management of CLL.
